15
Table 11. Antiplatelet Agents
COR LOE
Recommendations
I A Antiplatelet therapy with aspirin alone (range 75–325 mg per
day) or clopidogrel alone (75 mg per day) is recommended
to reduce MI, stroke, and vascular death in patients with
symptomatic PAD.
IIa C-EO In asymptomatic patients with PAD (ABI ≤0.90), antiplatelet
therapy is reasonable to reduce the risk of MI, stroke, or vascular
death.
IIb B-R In asymptomatic patients with borderline ABI (0.91–0.99), the
usefulness of antiplatelet therapy to reduce the risk of MI, stroke,
or vascular death is uncertain.
IIb B-R e effectiveness of dual-antiplatelet therapy (DAPT) (aspirin
and clopidogrel) to reduce the risk of cardiovascular ischemic
events in patients with symptomatic PAD is not well established.
IIb C-LD DAPT (aspirin and clopidogrel) may be reasonable to reduce the
risk of limb-related events in patients with symptomatic PAD
aer lower extremity revascularization.
IIb B-R e overall clinical benefit of vorapaxar added to existing
antiplatelet therapy in patients with symptomatic PAD is
uncertain.
Treatment
Table 12. Statin Agents
COR LOE
Recommendation
I A Treatment with a statin medication is indicated for all patients
with PAD.
Table 13. Antihypertensive Agents
COR LOE
Recommendations
I A Antihypertensive therapy should be administered to patients with
hypertension and PAD to reduce the risk of MI, stroke, heart
failure, and cardiovascular death.
IIa A e use of angiotensin-converting enzyme inhibitors or
angiotensin-receptor blockers can be effective to reduce the risk
of cardiovascular ischemic events in patients with PAD.
